Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Operations (2016 - 2025)

Voyager Therapeutics' Cash from Operations history spans 11 years, with the latest figure at 30263000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 108.29% year-over-year to 30263000.0; the TTM value through Dec 2025 reached 132467000.0, down 765.23%, while the annual FY2025 figure was 132467000.0, 765.23% down from the prior year.
  • Cash from Operations for Q4 2025 was 30263000.0 at Voyager Therapeutics, up from 31048000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 123565000.0 in Q1 2023 and bottomed at 37895000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 20880000.0 (2021), against an average of 6794600.0.
  • The largest annual shift saw Cash from Operations surged 261.67% in 2022 before it crashed 3682.04% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 11195000.0 in 2021, then plummeted by 209.37% to 12244000.0 in 2022, then crashed by 94.05% to 23760000.0 in 2023, then surged by 38.85% to 14529000.0 in 2024, then crashed by 108.29% to 30263000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Cash from Operations are 30263000.0 (Q4 2025), 31048000.0 (Q3 2025), and 33261000.0 (Q2 2025).